Issues relating to prescription benefit manager transparency; S.1339-Pharmacy Benefit Manager Reform Act; H.R. 5378-The Lower Costs, More Transparency Act; S. 1542/H.R. 6283 The Delinking Revenue from Unfair Gouging (DRUG) Act-provisions dictating PBM contracting terms.
S. 2973-Modernizing and Ensuring PBM Accountability Act; S. 3430-Better Mental Health Care, Lower-Cost Drugs, and Extenders Act relating to Title 2 reducing prescription drug costs.
Duration: February 1, 2019
to
present
General Issues: Health Issues , Medicare/Medicaid , Budget/Appropriations
Spending: about $618,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2019: U.S. Senate, House of Representatives
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
H.W. Menn III
Chief of Staff, Sen. Bob Graham; Minority Staff Director & Counsel, Sen. Cmte on Veterans Affairs; Sp. Asst. Legislative Affairs, FDA Office of Commissioner.
Henry Menn III
Chief of Staff, Sen. Bob Graham; Minority Staff Director & Counsel, Sen. Cmte on Veterans Affairs; Sp. Asst. Legislative Affairs, FDA Office of Commissioner.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, GOVERNMENT COUNSEL, LLC lobbied for Prime Therapeutics , earning $30,000. The report was filed on April 18.
Original Filing: 301553816.xml
Lobbying Issues
Issues relating to prescription benefit manager transparency; S.1339-Pharmacy Benefit Manager Reform Act; H.R. 5378-The Lower Costs, More Transparency Act; S. 1542/H.R. 6283 The Delinking Revenue from Unfair Gouging (DRUG) Act-provisions dictating PBM contracting terms.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S. 2973-Modernizing and Ensuring PBM Accountability Act; S. 3430-Better Mental Health Care, Lower-Cost Drugs, and Extenders Act relating to Title 2 reducing prescription drug costs.
4th Quarter, 2023
In Q4, GOVERNMENT COUNSEL, LLC lobbied for Prime Therapeutics , earning $30,000. The report was filed on Jan. 22.
Original Filing: 301535332.xml
Lobbying Issues
Issues relating to prescription benefit manager transparency; S.1339-Pharmacy Benefit Manager Reform Act; H.R. 5378-The Lower Costs, More Transparency Act; S. 1542/H.R. 6283 The Delinking Revenue from Unfair Gouging (DRUG) Act-provisions dictating PBM contracting terms.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S. 2973-Modernizing and Ensuring PBM Accountability Act; S. 3430-Better Mental Health Care, Lower-Cost Drugs, and Extenders Act relating to Title 2 reducing prescription drug costs.
3rd Quarter, 2023
In Q3, GOVERNMENT COUNSEL, LLC lobbied for Prime Therapeutics , earning $30,000. The report was filed on Oct. 16, 2023.
Original Filing: 301501711.xml
Lobbying Issues
Issues relating to prescription benefit manager transparency; S.1339-Pharmacy Benefit Manager Reform Act; H.R. 5378-The Lower Costs, More Transparency Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S. 2973-Modernizing and Ensuring PBM Accountability Act.
2nd Quarter, 2023
In Q2, GOVERNMENT COUNSEL, LLC lobbied for Prime Therapeutics , earning $30,000. The report was filed on July 20, 2023.
Original Filing: 301492388.xml
Lobbying Issues
Issues relating to prescription benefit manager transparency; S.1339-Pharmacy Benefit Manager Reform Act, H.R.4508-Hidden Fee Disclosure Act, H.R. 3561-The Patient Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2023
In Q1, GOVERNMENT COUNSEL, LLC lobbied for Prime Therapeutics , earning $30,000. The report was filed on April 17, 2023.
Original Filing: 301453789.xml
Lobbying Issues
Issues relating to prescription benefit manager transparency; S.127-Pharmacy Benefit Manager Transparency Act of 2023
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2022
In Q4, GOVERNMENT COUNSEL, LLC lobbied for Prime Therapeutics , earning $30,000. The report was filed on Jan. 16, 2023.
Original Filing: 301428024.xml
Lobbying Issues
Public Law 117-328-Consolidated Appropriations Act, 2023, relating oversight of PBM services and S.4293 (Pharmacy Benefit Manager Transparency Act of 2022).
3rd Quarter, 2022
In Q3, GOVERNMENT COUNSEL, LLC lobbied for Prime Therapeutics , earning $30,000. The report was filed on Oct. 18, 2022.
Original Filing: 301407305.xml
Lobbying Issues
General issues relating to oversight of PBM services, government negotiated drug pricing and Part D cost sharing; The Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs (CMS4192P) Proposed Rule relating to pharmacy direct and indirect remuneration.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S. 2199-Insulin Price Reduction Act; S.4293-Pharmacy Benefit Manager Transparency Act of 2022; S. 1388-Prescription Pricing for the People Act of 2021.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Monitor issues relating to insulin pricing in the Inflation Reduction Act (H.R. 5376).
2nd Quarter, 2022
In Q2, GOVERNMENT COUNSEL, LLC lobbied for Prime Therapeutics , earning $30,000. The report was filed on July 20, 2022.
Original Filing: 301391270.xml
Lobbying Issues
General issues relating to oversight of PBM services, government negotiated drug pricing and Part D cost sharing; The Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs (CMS4192P) Proposed Rule relating to pharmacy direct and indirect remuneration.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S. 2199-Insulin Price Reduction Act; S.4293-Pharmacy Benefit Manager Transparency Act of 2022; S. 1388-Prescription Pricing for the People Act of 2021.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2022
In Q1, GOVERNMENT COUNSEL, LLC lobbied for Prime Therapeutics , earning $30,000. The report was filed on April 17, 2022.
Original Filing: 301357762.xml
Lobbying Issues
General issues relating to oversight of PBM services, government negotiated drug pricing and Part D cost sharing; The Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs (CMS4192P) Proposed Rule relating to pharmacy direct and indirect remuneration.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2021
In Q4, GOVERNMENT COUNSEL, LLC lobbied for Prime Therapeutics , earning $30,000. The report was filed on Jan. 22, 2022.
Original Filing: 301339449.xml
Lobbying Issues
H.R. 5376 - Build Back Better Act relating to oversight of PBM services, government negotiated drug pricing and Part D cost sharing and the Final Rule on Removal of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection (RIN: 0936-AA080); Policies relating to pharmacy direct and indirect remuneration in Medicare Part D; S.2327 - Seniors Prescription Drug Relief Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2021
In Q3, GOVERNMENT COUNSEL, LLC lobbied for Prime Therapeutics , earning $30,000. The report was filed on Oct. 18, 2021.
Original Filing: 301301313.xml
Lobbying Issues
Removal of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection Final Rule (RIN: 0936-AA080);Build Back Better Act relating to government negotiated drug pricing and Part D cost sharing; Policies relating to pharmacy direct and indirect remuneration in Medicare Part D; S.2327 - Seniors Prescription Drug Relief Act by Cassidy/Menendez.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2021
In Q2, GOVERNMENT COUNSEL, LLC lobbied for Prime Therapeutics , earning $30,000. The report was filed on July 19, 2021.
Original Filing: 301281661.xml
Lobbying Issues
Removal of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection Final Rule (RIN: 0936-AA080); Issues relating to Medicare Part D beneficiary cost sharing; Direct and indirect remuneration (DIR) fees; H.R.3-Elijah E. Cummings Lower Drug Costs Now Act relating to government drug price negotiation.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2021
In Q1, GOVERNMENT COUNSEL, LLC lobbied for Prime Therapeutics , earning $30,000. The report was filed on April 19, 2021.
Original Filing: 301257414.xml
Lobbying Issues
Removal of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection Final Rule (RIN: 0936-AA080); Issues relating to Medicare Part D beneficiary cost sharing.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2020
In Q4, GOVERNMENT COUNSEL, LLC lobbied for Prime Therapeutics , earning $30,000. The report was filed on Jan. 18, 2021.
Original Filing: 301232966.xml
Lobbying Issues
S. 1895-Lower Health Care Costs Actrelating to 306;Removal of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection Final Rule (RIN: 0936-AA080).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues relating to pharmacy direct and indirect remuneration in Medicare Part D.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 133-Consolidated Appropriations Act of 2021 relating to PBM transparency and disclosure.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2020
In Q3, GOVERNMENT COUNSEL, LLC lobbied for Prime Therapeutics , earning $30,000. The report was filed on Oct. 16, 2020.
Original Filing: 301211711.xml
Lobbying Issues
S. 1895-Lower Health Care Costs ActSection 306; H.R. 6800- Health and Economic Recovery Omnibus Emergency Solutions Act (HERO) Section 30205.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues relating to pharmacy direct and indirect remuneration in Medicare Part D and on real time benefit tools; Executive Order 13939 on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2020
In Q2, GOVERNMENT COUNSEL, LLC lobbied for Prime Therapeutics , earning $30,000. The report was filed on July 17, 2020.
Original Filing: 301191996.xml
Lobbying Issues
S. 1895-Lower Health Care Costs ActSection 306;S. 2543-The Prescription Drug Pricing Reduction Act (PDPRA) of 2019; H.R. 3-Lower Drug Costs Now Act of 2019 relating to pharmacy DIR;H.R. 748-Coronavirus Aid, Relief, and Economic Security Act relating to pharmacy DIR;H.R. 6800- Health and Economic Recovery Omnibus Emergency Solutions Act (HERO); 21st Century CURES 2.0 relating to value-based purchasing.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2020
In Q1, GOVERNMENT COUNSEL, LLC lobbied for Prime Therapeutics , earning $30,000. The report was filed on April 15, 2020.
Original Filing: 301166846.xml
Lobbying Issues
S. 1895-Lower Health Care Costs ActSection 306;S. 2543-The Prescription Drug Pricing Reduction Act (PDPRA) of 2019; H.R. 3-Lower Drug Costs Now Act of 2019 relating to pharmacy DIR; H.R. 5304-PBM Transparency in Prescription Drug Costs Act; H.R. 748-Coronavirus Aid, Relief, and Economic Security Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
General issues relating to PBM point of sale rebates, spread pricing and price transparency.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2019
In Q4, GOVERNMENT COUNSEL, LLC lobbied for Prime Therapeutics , earning $30,000. The report was filed on Jan. 20, 2020.
Original Filing: 301122315.xml
Lobbying Issues
S. 1895-Lower Health Care Costs ActSection 306;S. 2543-The Prescription Drug Pricing Reduction Act (PDPRA) of 2019; H.R. 3-Lower Drug Costs Now Act of 2019 relating to pharmacy DIR;H.R. 5304-PBM Transparency in Prescription Drug Costs Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
General issues relating to PBM point of sale rebates, spread pricing and price transparency.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2019
In Q3, GOVERNMENT COUNSEL, LLC lobbied for Prime Therapeutics , earning $30,000. The report was filed on Oct. 21, 2019.
Original Filing: 301078647.xml
Lobbying Issues
H.R. 2113-Prescription Drug STAR Act of 2019;H.R. 2296-More Efficient Tools to Realize Information for Consumers (METRIC) Act;S. 1895-Lower Health Care Costs ActSection 306;S. 2543-The Prescription Drug Pricing Reduction Act (PDPRA) of 2019; H.R. 3-Lower Drug Costs Now Act of 2019 relating to pharmacy DIR.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
General issues relating to PBM point of sale rebates, spread pricing and price transparency.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2019
In Q2, GOVERNMENT COUNSEL, LLC lobbied for Prime Therapeutics , earning $30,000. The report was filed on July 17, 2019.
Original Filing: 301048263.xml
Lobbying Issues
RIN 0936-AA08: Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees; S.476-The Creating Transparency to Have Drug Rebates Unlocked Act; S. 1895-Lower Health Care Costs ActSection relating to Section 306; H.R. 2113-Prescription Drug Sunshine, Transparency, Accountability and Reporting (STAR) Act of 2019; H.R. 2376- & S. 1227-The Prescription Pricing for the People Act; H.R.- 2115, the Public Disclosures of Drug Discounts Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
General issues relating to PBM point of sale rebates, spread pricing and price transparency.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2019
In Q1, GOVERNMENT COUNSEL, LLC lobbied for Prime Therapeutics , earning $18,000. The report was filed on April 17, 2019.
Original Filing: 301027427.xml
Lobbying Issues
H.R 1781- Payment Commission Data Act of 2019; H.R. 965 & S. 340-The CREATES Act of 2019; issues relating to orphan drug exclusivity and value-based contracting; RIN 0936-AA08: Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees; S.476-The Creating Transparency to Have Drug Rebates Unlocked Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2019
GOVERNMENT COUNSEL LLC filed a lobbying registration on Feb. 5, 2019 to represent Prime Therapeutics, effective Feb. 1, 2019.
Original Filing: 301019859.xml
Issue(s) they said they’d lobby about: Issues relating to pharmaceutical value-based contracting and rebate transparency. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate